Effects of Tofacitinib on Bone Marrow Edema, Synovitis, and Erosive Damage in Methotrexate-Naive Patients with Early Active Rheumatoid Arthritis (Duration ≤2 Years): Results of an Exploratory Phase 2 MRI Study.

被引：0

作者：

Conaghan, Philip G. ^{[1
,2
]}

Ostergaard, M. ^{[3
]}

Wu, C. ^{[4
]}

van der Heijde, D. ^{[5
]}

Irazoque-Palazuelos, F. ^{[6
]}

Hrycaj, P. ^{[7
]}

Xie, Z. ^{[8
]}

Zhang, R. ^{[8
]}

Wyman, B. T. ^{[8
]}

Bradley, J. D. ^{[8
]}

Soma, K. ^{[8
]}

Wilkinson, B. ^{[8
]}

机构：

[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[2] Chapel Allerton Hosp, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England

[3] Copenhagen Ctr Arthrit Res, Glostrup, Denmark

[4] BioClinca Inc, Newark, CA USA

[5] Leiden Univ, Med Ctr, Leiden, Netherlands

[6] Hosp Angeles Mocel, Serv Reumatol, Mexico City, DF, Mexico

[7] Poznan Univ Med Sci, Poznan, Poland

[8] Pfizer Inc, Groton, CT 06340 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1181

引用

页码：S519 / S520

页数：2

共 38 条

[31] LOW RATES OF RADIOGRAPHIC PROGRESSION WITH 2 YEARS OF GUSELKUMAB, A SELECTIVE INHIBITOR OF THE INTERLEUKIN-23P19 SUBUNIT: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Mease, P. J.
Gottlieb, A. B.
Mcinnes, I.
Rahman, P.
Kollmeier, A.
Xu, X. L.
Jiang, Y.
Sheng, S.
Shawi, M.
Chakravarty, S. D.
Lavie, F.
Van der Heijde, D.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 831 - 832
[32] Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis
Gladman, Dafna
Starr, Michael
Ranza, Roberto
Perdomo, Ana
Strauss, Marcie
Shawi, May
Han, Chenglong
Rampakakis, Emmanouil
Ostor, Andrew
Mease, Philip
JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 79 - 79
[33] Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naive Patients with Active Psoriatic Arthritis
Gladman, Dafna
Starr, Michael
Ranza, Roberto
Perdomo, Ana-Maria Bravo
Strauss, Marcie
Shawi, May
Han, Chenglong
Rampakakis, Emmanouil
Ostor, Andrew
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4175 - 4178
[34] LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Gladman, D. D.
Starr, M.
Ranza, R.
Bravo Perdomo, A. M.
Strauss, M.
Shawi, M.
Han, C.
Rampakakis, E.
Ostor, A. Andrew
Mease, P. J.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1765 - 1765
[35] Low Rates of Radiographic Progression with 2 Years of Guselkumab (TREMFYA®), a Selective Inhibitor of the Interleukin-23p19 Subunit: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study of Biologic-naive Patients with Active Psoriatic Arthritis
Mease, Philip
Gottlieb, Alice
McInnes, Iain
Rahman, Proton
Kollmeier, Alexa
Xu, Xie
Jiang, Yusang
Sheng, Shihong
Shawi, May
Chakravarty, Soumya
Lavie, Frederic
van der Heijde, Desiree
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3763 - 3765
[36] EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE p19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2 YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Mcinnes, I.
Rahman, P.
Gottlieb, A. B.
Hsia, E. C.
Kollmeier, A.
Xu, X. L.
Sheng, S.
Jiang, Y.
Shawi, M.
Chakravarty, S. D.
Van der Heijde, D.
Mease, P. J.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 783 - 784
[37] Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naive Patients with Active Psoriatic Arthritis
McInnes, Iain
Rahman, Proton
Gottlieb, Alice
Hsia, Elizabeth
Kollmeier, Alexa
Xu, Xie
Sheng, Shihong
Jiang, Yusang
Shawi, May
Chakravarty, Soumya
van der Heijde, Desiree
Mease, Philip
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2777 - 2779
[38] EFFICACY AND SAFETY-OF GUSELKUMAB, A NIONOCLONAL ANTIBODY SPECIFIC TO THE P19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Soriano, Enrique R.
Mcinnes, Iain B.
Rahman, Proton
Gottlieb, Alice R.
Hsia, Elizabeth C.
Kollmeier, Alexa P.
Xu, Xie L.
Sheng, Shihong
Jiang, Yusang
Shawi, May
Chakravarty, Soumya A.
Van der Heijde, Desiree
Mease, Philip J.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S93 - S93

← 1 2 3 4 →